Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract #849: Anti-\#946;2-microglobulin monoclonal antibody inhibition of androgen receptor expression and survival through a lipogenic pathway in prostate cancer

Wen-Chin Huang, Guodong Zhu, Haiyen E. Zhau and Leland W. K. Chung
Wen-Chin Huang
Emory University Winship Cancer Institute, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guodong Zhu
Emory University Winship Cancer Institute, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haiyen E. Zhau
Emory University Winship Cancer Institute, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leland W. K. Chung
Emory University Winship Cancer Institute, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

\#946;2-Microglobulin (\#946;2M) is a critical promoter of osteomimicry and cell proliferation in human prostate cancer cells through a cAMP/protein kinase A (PKA)/cAMP-responsive element binding protein (CREB) signaling pathway (Huang et al., Cancer Res., 65:2303-13, 2005). Blockade of \#946;2M and its related signaling axis using a new agent, anti-\#946;2M monoclonal antibody (\#946;2M mAb), inhibited mRNA and protein expression of androgen receptor (AR) and its target gene, prostate-specific antigen (PSA), in prostate cancer cells and induced programmed death of prostate cancer cells by activating a caspase-9 dependent pathway, in vitro and in vivo. The molecular mechanism by which \#946;2M mAb inhibited AR expression was through decreasing the interaction between a lipogenic transcription factor, sterol regulatory element-binding protein-1 (SREBP-1), and its binding cis-acting element located in the 5\#8217;-flanking AR promoter region, as determined by electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation assay (ChIP). The functional study of SREBP-1 revealed that knocking down or overexpressing SREBP-1 using sequence-specific siRNA or an expression vector decreased or increased total and nuclear AR proteins and cell viability in prostate cancer cells. SREBP-1 has been identified and reported as a key regulator of genes involved in fatty acid and cholesterol biosynthesis. Inhibiting AR expression by \#946;2M mAb also significantly decreased SREBP-1 expression and fatty acid contents in prostate cancer cells, which are important for cell membrane construction and energy storage. In summary, \#946;2M mAb may be a potent and attractive pleiotropic therapeutic agent that can inhibit AR expression, lipid metabolism, cell proliferation and survival in prostate cancer cells through down-regulation of a lipogenic pathway.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 849.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #849: Anti-\#946;2-microglobulin monoclonal antibody inhibition of androgen receptor expression and survival through a lipogenic pathway in prostate cancer
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #849: Anti-\#946;2-microglobulin monoclonal antibody inhibition of androgen receptor expression and survival through a lipogenic pathway in prostate cancer
Wen-Chin Huang, Guodong Zhu, Haiyen E. Zhau and Leland W. K. Chung
Cancer Res May 1 2009 (69) (9 Supplement) 849;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #849: Anti-\#946;2-microglobulin monoclonal antibody inhibition of androgen receptor expression and survival through a lipogenic pathway in prostate cancer
Wen-Chin Huang, Guodong Zhu, Haiyen E. Zhau and Leland W. K. Chung
Cancer Res May 1 2009 (69) (9 Supplement) 849;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Kinases and Other Membrane Targets -- Poster Presentations - Proffered Abstracts

  • Abstract #853: New ALK5 inhibitor as an anti-metastasis agent in both human breast cancer cells and MMTV/cNeu transgenic mice
  • Abstract #857: Characterization of genetic factors associated with sensitivity to Irvalec, a novel marine-derived compound.
  • Abstract #860: Monoclonal antibodies to non-ligand-binding sites on CD30 induce agonistic effects and growth inhibition of human lymphoma cells
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement